Back to results
US 2019/0338038 A1Published application
Anti-il1-rap antibodies
AssigneeCellerant Therapeutics, Inc.
InventorsYing Ping Jiang, Jagath R. Junutula, Leonard G. Presta
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies specific for IL1-RAP.
Claims21
1-84. (canceled)
An isolated anti-IL1-RAP antibody comprising a variable light chain and a variable heavy chain, wherein:
- a) the variable light chain comprises a sequence having a CDRL1, CDRL2 and CDRL3 each having at least 95% sequence identity to a CDRL1, CDRL2 and CDRL3, respectively, of an antibody selected from the group consisting of:
- 54.9D7, 56.12G6, 2H8, 50.3G7, 54.15B5, 42.1D3, 54.8H8, 54.9E9, 50.6C12, 57.7A9, 46.8G1, 42.3G6, 46.1D2, 41.10C2, 46.2C2, 44.5D2;
- and/or
- b) the variable heavy chain comprises a sequence having a CDRH1, CDRH2, CDRH3 each having at least 95% sequence identity to a CDRH1, CDRH2, CDRH3, respectively, sequence of an antibody selected from the group consisting of:
- 54.9D7, 56.12G6, 2H8, 50.3G7, 54.15B5, 42.1D3, 54.8H8, 54.9E9, 50.6C12, 57.7A9, 46.8G1, 42.3G6, 46.1D2, 41.10C2, 46.2C2, 44.5D2.
2 more elements
Dependencies are inferred from the claim text.